Risk factors and chemoprevention in Barrett's esophagus – an update

References

• Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005;97:142–6.
   PubMed Web of Science ®Google Scholar
• Sikkema M, de Jonge PJ, Steyerberg EW, Kuipers EJ. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2010;8:235–44; quiz e232.
   PubMed Web of Science ®Google Scholar
• Yousef F, Cardwell C, Cantwell MM, Galway K, Johnston BT, Murray L. The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. Am J Epidemiol 2008;168:237–49.
   PubMed Web of Science ®Google Scholar
• Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 2011;365:1375–83.
   PubMed Web of Science ®Google Scholar
• de Jonge PJ, van Blankenstein M, Looman CW, Casparie MK, Meijer GA, Kuipers EJ. Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study. Gut 2010;59:1030–6.
   PubMed Web of Science ®Google Scholar
• Jankowski JA, Provenzale D, Moayyedi P. Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the west. Gastroenterology 2002;122:588–90.
   PubMed Web of Science ®Google Scholar
• Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008;103:788–97.
   PubMed Web of Science ®Google Scholar
• Westhoff B, Brotze S, Weston A, McElhinney C, Cherian R, Mayo MS, The frequency of Barrett's esophagus in high-risk patients with chronic GERD. Gastrointest Endosc 2005;61:226–31.
   PubMed Web of Science ®Google Scholar
• Ford AC, Forman D, Reynolds PD, Cooper BT, Moayyedi P. Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett's esophagus. Am J Epidemiol 2005;162:454–60.
   PubMed Web of Science ®Google Scholar
• Rex DK, Cummings OW, Shaw M, Cumings MD, Wong RK, Vasudeva RS, Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology 2003;125:1670–7.
   PubMed Web of Science ®Google Scholar
• Ronkainen J, Aro P, Storskrubb T, Johansson SE, Lind T, Bolling-Sternevald E, Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 2005;129:1825–31.
   PubMed Web of Science ®Google Scholar
• Spechler SJ, Zeroogian JM, Antonioli DA, Wang HH, Goyal RK. Prevalence of metaplasia at the gastro-oesophageal junction. Lancet 1994;344:1533–6.
   PubMed Web of Science ®Google Scholar
• Abrams JA, Fields S, Lightdale CJ, Neugut AI. Racial and ethnic disparities in the prevalence of Barrett's esophagus among patients who undergo upper endoscopy. Clin Gastroenterol Hepatol 2008;6:30–4.
   PubMedGoogle Scholar
• Zhang J, Chen XL, Wang KM, Guo XD, Zuo AL, Gong J. Barrett's esophagus and its correlation with gastroesophageal reflux in Chinese. World J Gastroenterol 2004;10:1065–8.
   PubMedGoogle Scholar
• Rees JR, Lao-Sirieix P, Wong A, Fitzgerald RC. Treatment for Barrett's oesophagus. Cochrane Database Syst Rev 2010;CD004060.
   Google Scholar
• Spechler SJ, Fitzgerald RC, Prasad GA, Wang KK. History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus. Gastroenterology 2010;138:854–69.
   PubMed Web of Science ®Google Scholar
• Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101:1900–1920– quiz 1943.
   PubMed Web of Science ®Google Scholar
• Woodland P, Sifrim D. The refluxate: the impact of its magnitude, composition and distribution. Best Pract Res Clin Gastroenterol 2010;24:861–71.
   PubMed Web of Science ®Google Scholar
• Eloubeidi MA, Provenzale D. Clinical and demographic predictors of Barrett's esophagus among patients with gastroesophageal reflux disease: a multivariable analysis in veterans. J Clin Gastroenterol 2001;33:306–9.
   PubMed Web of Science ®Google Scholar
• Johansson J, Hakansson HO, Mellblom L, Kempas A, Johansson KE, Granath F, Risk factors for Barrett's oesophagus: a population-based approach. Scand J Gastroenterol 2007;42:148–56.
   PubMed Web of Science ®Google Scholar
• Smith KJ, O'Brien SM, Smithers BM, Gotley DC, Webb PM, Green AC, Interactions among smoking, obesity, and symptoms of acid reflux in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2005;14:2481–6.
   PubMed Web of Science ®Google Scholar
• Winters C Jr, Spurling TJ, Chobanian SJ, Curtis DJ, Esposito RL, Hacker JF 3rd,, Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987;92:118–24.
   PubMed Web of Science ®Google Scholar
• Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825–31.
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Lind T, Willich S, Vieth M, Jaspersen D, Labenz J, Prognostic influence of Barrett's oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study. Gut 2005;54:746–51.
   PubMed Web of Science ®Google Scholar
• Voutilainen M, Sipponen P, Mecklin JP, Juhola M, Farkkila M. Gastroesophageal reflux disease: prevalence, clinical, endoscopic and histopathological findings in 1,128 consecutive patients referred for endoscopy due to dyspeptic and reflux symptoms. Digestion 2000;61:6–13.
   PubMed Web of Science ®Google Scholar
• Campos GM, DeMeester SR, Peters JH, Oberg S, Crookes PF, Hagen JA, Predictive factors of Barrett esophagus: multivariate analysis of 502 patients with gastroesophageal reflux disease. Arch Surg 2001;136:1267–73.
   PubMedGoogle Scholar
• Theodorou D, Ayazi S, Demeester SR, Zehetner J, Peyre CG, Grant KS, Intraluminal pH and goblet cell density in Barrett's esophagus. J Gastrointest Surg 2011;16:469–74.
   PubMedGoogle Scholar
• Conio M, Filiberti R, Blanchi S, Ferraris R, Marchi S, Ravelli P, Risk factors for Barrett's esophagus: a case-control study. Int J Cancer 2002;97:225–9.
   PubMed Web of Science ®Google Scholar
• Eisen GM, Sandler RS, Murray S, Gottfried M. The relationship between gastroesophageal reflux disease and its complications with Barrett's esophagus. Am J Gastroenterol 1997;92:27–31.
   PubMed Web of Science ®Google Scholar
• Lieberman DA, Oehlke M, Helfand M. Risk factors for Barrett's esophagus in community-based practice. GORGE consortium. Gastroenterology outcomes research group in endoscopy. Am J Gastroenterol 1997;92:1293–7.
   PubMed Web of Science ®Google Scholar
• Avidan B, Sonnenberg A, Schnell TG, Sontag SJ. Hiatal hernia and acid reflux frequency predict presence and length of Barrett's esophagus. Dig Dis Sci 2002;47:256–64.
   PubMed Web of Science ®Google Scholar
• Banki F, Demeester SR, Mason RJ, Campos G, Hagen JA, Peters JH, Barrett's esophagus in females: a comparative analysis of risk factors in females and males. Am J Gastroenterol 2005;100:560–7.
   PubMedGoogle Scholar
• Cameron AJ. Barrett's esophagus: prevalence and size of hiatal hernia. Am J Gastroenterol 1999;94:2054–9.
   PubMed Web of Science ®Google Scholar
• Zagari RM, Fuccio L, Wallander MA, Johansson S, Fiocca R, Casanova S, Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study. Gut 2008;57:1354–9.
   PubMed Web of Science ®Google Scholar
• Corley DA, Kubo A, Levin TR, Block G, Habel L, Rumore G, Race, ethnicity, sex and temporal differences in Barrett's oesophagus diagnosis: a large community-based study, 1994–2006. Gut 2009;58:182–8.
   PubMed Web of Science ®Google Scholar
• Edelstein ZR, Bronner MP, Rosen SN, Vaughan TL. Risk factors for Barrett's esophagus among patients with gastroesophageal reflux disease: a community clinic-based case-control study. Am J Gastroenterol 2009;104:834–42.
   PubMed Web of Science ®Google Scholar
• Lofdahl HE, Lu Y, Lagergren J. Sex-specific risk factor profile in oesophageal adenocarcinoma. Br J Cancer 2008;99:1506–10.
   PubMedGoogle Scholar
• Nilsson M, Johnsen R, Ye W, Hveem K, Lagergren J. Prevalence of gastro-oesophageal reflux symptoms and the influence of age and sex. Scand J Gastroenterol 2004;39:1040–5.
   PubMed Web of Science ®Google Scholar
• Cook MB, Wild CP, Forman D. A systematic review and meta-analysis of the sex ratio for Barrett's esophagus, erosive reflux disease, and nonerosive reflux disease. Am J Epidemiol 2005;162:1050–61.
   PubMed Web of Science ®Google Scholar
• Falk J, Carstens H, Lundell L, Albertsson M. Incidence of carcinoma of the oesophagus and gastric cardia. Changes over time and geographical differences. Acta Oncol 2007;46:1070–4.
   PubMed Web of Science ®Google Scholar
• Adeniyi KO. Gastric acid secretion and parietal cell mass: effect of sex hormones. Gastroenterology 1991;101:66–9.
   PubMed Web of Science ®Google Scholar
• Corley DA, Kubo A, Levin TR, Block G, Habel L, Zhao W, Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology 2007;133:34–41; quiz 311.
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Kvapil P, Hacken-Bitar J, Kramer JR. Abdominal obesity and the risk of Barrett's esophagus. Am J Gastroenterol 2005;100:2151–6.
   PubMed Web of Science ®Google Scholar
• Jacobson BC, Chan AT, Giovannucci EL, Fuchs CS. Body mass index and Barrett's oesophagus in women. Gut 2009;58:1460–6.
   PubMed Web of Science ®Google Scholar
• Bu X, Ma Y, Der R, Demeester T, Bernstein L, Chandrasoma PT. Body mass index is associated with Barrett esophagus and cardiac mucosal metaplasia. Dig Dis Sci 2006;51:1589–94.
   PubMed Web of Science ®Google Scholar
• Kamat P, Wen S, Morris J, Anandasabapathy S. Exploring the association between elevated body mass index and Barrett's esophagus: a systematic review and meta-analysis. Ann Thorac Surg 2009;87:655–62.
   PubMedGoogle Scholar
• Edelstein ZR, Farrow DC, Bronner MP, Rosen SN, Vaughan TL. Central adiposity and risk of Barrett's esophagus. Gastroenterology 2007;133:403–11.
   PubMed Web of Science ®Google Scholar
• Cook MB, Greenwood DC, Hardie LJ, Wild CP, Forman D. A systematic review and meta-analysis of the risk of increasing adiposity on Barrett's esophagus. Am J Gastroenterol 2008;103:292–300.
   PubMed Web of Science ®Google Scholar
• Nilsson M, Johnsen R, Ye W, Hveem K, Lagergren J. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. JAMA 2003;290:66–72.
   PubMed Web of Science ®Google Scholar
• Kendall BJ, Macdonald GA, Hayward NK, Prins JB, Brown I, Walker N, Leptin and the risk of Barrett's oesophagus. Gut 2008;57:448–54.
   PubMed Web of Science ®Google Scholar
• Thompson OM, Beresford SA, Kirk EA, Bronner MP, Vaughan TL. Serum leptin and adiponectin levels and risk of Barrett's esophagus and intestinal metaplasia of the gastroesophageal junction. Obesity (Silver Spring) 2010;18:2204–11.
   PubMedGoogle Scholar
• Cameron AJ, Lomboy CT. Barrett's esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology 1992;103:1241–5.
   PubMed Web of Science ®Google Scholar
• Caygill CP, Reed PI, Johnston BJ, Hill MJ, Ali MH, Levi S. A single centre's 20 years' experience of columnar-lined (Barrett's) oesophagus diagnosis. Eur J Gastroenterol Hepatol 1999;11:1355–8.
   PubMedGoogle Scholar
• Tseng PH, Lee YC, Chiu HM, Huang SP, Liao WC, Chen CC, Prevalence and clinical characteristics of Barrett's esophagus in a Chinese general population. J Clin Gastroenterol 2008;42:1074–9.
   PubMed Web of Science ®Google Scholar
• Park JJ, Kim JW, Kim HJ, Chung MG, Park SM, Baik GH, The prevalence of and risk factors for Barrett's esophagus in a Korean population: A nationwide multicenter prospective study. J Clin Gastroenterol 2009;43:907–14.
   PubMedGoogle Scholar
• Yeh C, Hsu CT, Ho AS, Sampliner RE, Fass R. Erosive esophagitis and Barrett's esophagus in Taiwan: a higher frequency than expected. Dig Dis Sci 1997;42:702–6.
   PubMedGoogle Scholar
• Lofdahl HE, Lane A, Lu Y, Lagergren P, Harvey RF, Blazeby JM, Increased population prevalence of reflux and obesity in the United Kingdom compared with Sweden: a potential explanation for the difference in incidence of esophageal adenocarcinoma. Eur J Gastroenterol Hepatol 2011;23:128–32.
   PubMed Web of Science ®Google Scholar
• Chak A, Lee T, Kinnard MF, Brock W, Faulx A, Willis J, Familial aggregation of Barrett's oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in Caucasian adults. Gut 2002;51:323–8.
   PubMed Web of Science ®Google Scholar
• Gelfand MD. Barrett esophagus in sexagenarian identical twins. J Clin Gastroenterol 1983;5:251–3.
   PubMedGoogle Scholar
• Jochem VJ, Fuerst PA, Fromkes JJ. Familial Barrett's esophagus associated with adenocarcinoma. Gastroenterology 1992;102:1400–2.
   PubMed Web of Science ®Google Scholar
• Cameron AJ, Lagergren J, Henriksson C, Nyren O, Locke GR 3rd,, Pedersen NL. Gastroesophageal reflux disease in monozygotic and dizygotic twins. Gastroenterology 2002;122:55–9.
   PubMed Web of Science ®Google Scholar
• Romero Y, Cameron AJ, Schaid DJ, McDonnell SK, Burgart LJ, Hardtke CL, Barrett's esophagus: prevalence in symptomatic relatives. Am J Gastroenterol 2002;97:1127–32.
   PubMed Web of Science ®Google Scholar
• Trudgill NJ, Kapur KC, Riley SA. Familial clustering of reflux symptoms. Am J Gastroenterol 1999;94:1172–8.
   PubMedGoogle Scholar
• Kubo A, Levin TR, Block G, Rumore G, Quesenberry CP Jr, Buffler P, Cigarette smoking and the risk of Barrett's esophagus. Cancer Causes Control 2009;20:303–11.
   PubMedGoogle Scholar
• Smith KJ, O'Brien SM, Green AC, Webb PM, Whiteman DC. Current and past smoking significantly increase risk for Barrett's esophagus. Clin Gastroenterol Hepatol 2009;7:840–8.
   PubMedGoogle Scholar
• Veugelers PJ, Porter GA, Guernsey DL, Casson AG. Obesity and lifestyle risk factors for gastroesophageal reflux disease, Barrett esophagus and esophageal adenocarcinoma. Dis Esophagus 2006;19:321–8.
   PubMedGoogle Scholar
• Anderson LA, Cantwell MM, Watson RG, Johnston BT, Murphy SJ, Ferguson HR, The association between alcohol and reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma. Gastroenterology 2009;136:799–805.
   PubMed Web of Science ®Google Scholar
• Kubo A, Levin TR, Block G, Rumore GJ, Quesenberry CP Jr, Buffler P, Alcohol types and sociodemographic characteristics as risk factors for Barrett's esophagus. Gastroenterology 2009;136:806–15.
   PubMedGoogle Scholar
• Huang JQ, Zheng GF, Sumanac K, Irvine EJ, Hunt RH. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology 2003;125:1636–44.
   PubMed Web of Science ®Google Scholar
• Corley DA, Kubo A, Levin TR, Block G, Habel L, Rumore G, Helicobacter pylori and gastroesophageal reflux disease: a case-control study. Helicobacter 2008;13:352–60.
   Google Scholar
• Corley DA, Kubo A, Levin TR, Block G, Habel L, Zhao W, Helicobacter pylori infection and the risk of Barrett's oesophagus: a community-based study. Gut 2008;57:727–33.
   PubMed Web of Science ®Google Scholar
• Sonnenberg A, Lash RH, Genta RM. A national study of Helicobactor pylori infection in gastric biopsy specimens. Gastroenterology 2010;139:1894–901; e1892; quiz e1812.
   PubMed Web of Science ®Google Scholar
• Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G. Relationship between Helicobacter pylor infection and esophageal neoplasia: a meta-analysis. Clin Gastroenterol Hepatol 2007;5:1413–17; 1417 e1411-1412.
   PubMed Web of Science ®Google Scholar
• Kubo A, Levin TR, Block G, Rumore GJ, Quesenberry CP Jr, Buffler P, Dietary antioxidants, fruits, and vegetables and the risk of Barrett's esophagus. Am J Gastroenterol 2008;103:1614–23; quiz 1624.
   PubMed Web of Science ®Google Scholar
• Ibiebele TI, Hughes MC, Pandeya N, Zhao Z, Montgomery G, Hayward N, High intake of folate from food sources is associated with reduced risk of esophageal cancer in an Australian population. J Nutr 2011;141:274–83.
   PubMed Web of Science ®Google Scholar
• Thompson OM, Beresford SA, Kirk EA, Vaughan TL. Vegetable and fruit intakes and risk of Barrett's esophagus in men and women. Am J Clin Nutr 2009;89:890–6.
   PubMed Web of Science ®Google Scholar
• Murphy SJ, Anderson LA, Ferguson HR, Johnston BT, Watson PR, McGuigan J, Dietary antioxidant and mineral intake in humans is associated with reduced risk of esophageal adenocarcinoma but not reflux esophagitis or Barrett's esophagus. J Nutr 2010;140:1757–63.
   PubMedGoogle Scholar
• Liao LM, Vaughan TL, Corley DA, Cook MB, Casson AG, Kamangar F, Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology 2012; in press.
   Google Scholar
• Sadeghi S, Bain CJ, Pandeya N, Webb PM, Green AC, Whiteman DC. Aspirin, nonsteroidal anti-inflammatory drugs, and the risks of cancers of the esophagus. Cancer Epidemiol Biomarkers Prev 2008;17:1169–78.
   PubMed Web of Science ®Google Scholar
• Anderson LA, Johnston BT, Watson RG, Murphy SJ, Ferguson HR, Comber H, Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. Cancer Res 2006;66:4975–82.
   PubMedGoogle Scholar
• Thrift AP, Pandeya N, Smith KJ, Green AC, Webb PM, Whiteman DC. The use of nonsteroidal anti-inflammatory drugs and the risk of Barrett's oesophagus. Aliment Pharmacol Ther 2011;34:1235–44.
   PubMedGoogle Scholar
• Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 1999;117:327–35.
   PubMed Web of Science ®Google Scholar
• Tselepis C, Morris CD, Wakelin D, Hardy R, Perry I, Luong QT, Upregulation of the oncogene c-myc in Barrett's adenocarcinoma: induction of c-myc by acidified bile acid in vitro. Gut 2003;52:174–80.
   PubMed Web of Science ®Google Scholar
• Cooper BT, Chapman W, Neumann CS, Gearty JC. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence. Aliment Pharmacol Ther 2006;23:727–33.
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Aguirre TV, Davis S, Kuebeler M, Bhattacharyya A, Sampliner RE. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 2004;99:1877–83.
   PubMed Web of Science ®Google Scholar
• Hillman LC, Chiragakis L, Shadbolt B, Kaye GL, Clarke AC. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust 2004;180:387–91.
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Petersen NJ, Carter J, Graham DY, Richardson P, Genta RM, Gastroesophageal reflux among different racial groups in the United States. Gastroenterology 2004;126:1692–9.
   PubMed Web of Science ®Google Scholar
• Nguyen DM, El-Serag HB, Henderson L, Stein D, Bhattacharyya A, Sampliner RE. Medication usage and the risk of neoplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2009;7:1299–304.
   PubMed Web of Science ®Google Scholar
• Islami F, Kamangar F, Boffetta P. Use of proton pump inhibitors and risk of progression of Barrett's esophagus to neoplastic lesions. Am J Gastroenterol 2009;104:2646–8.
   PubMedGoogle Scholar
• Leedham S, Jankowski J. The evidence base of proton pump inhibitor chemopreventative agents in Barrett's esophagus–the good, the bad, and the flawed! The American Journal of Gastroenterology. 2007;102:21–3.
   Google Scholar
• Soma T, Shimada Y, Kawabe A, Kaganoi J, Kondo K, Imamura M, Induction of prostaglandin E synthase by gastroesophageal reflux contents in normal esophageal epithelial cells and esophageal cancer cells. Dis Esophagus 2007;20:123–9.
   PubMedGoogle Scholar
• Cheng L, Harnett KM, Cao W, Liu F, Behar J, Fiocchi C, Hydrogen peroxide reduces lower esophageal sphincter tone in human esophagitis. Gastroenterology 2005;129:1675–85.
   PubMed Web of Science ®Google Scholar
• Shirvani VN, Ouatu-Lascar R, Kaur BS, Omary MB, Triadafilopoulos G. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. Gastroenterology 2000;118:487–96.
   PubMed Web of Science ®Google Scholar
• Buttar NS, Wang KK, Anderson MA, Dierkhising RA, Pacifico RJ, Krishnadath KK, The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study. J Natl Cancer Inst 2002;94:422–9.
   PubMedGoogle Scholar
• Vaughan TL, Dong LM, Blount PL, Ayub K, Odze RD, Sanchez CA, Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol 2005;6:945–52.
   PubMedGoogle Scholar
• Kastelein F, Spaander MC, Biermann K, Steyerberg EW, Kuipers EJ, Bruno MJ. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus. Gastroenterology 2011;141:2000–8.
   PubMed Web of Science ®Google Scholar
• Nguyen DM, Richardson P, El-Serag HB. Medications (NSAID, Statins, PPI) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology 2010;138:2260–6.
   PubMed Web of Science ®Google Scholar
• Heath EI, Canto MI, Piantadosi S, Montgomery E, Weinstein WM, Herman JG, Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst 2007;99:545–57.
   PubMed Web of Science ®Google Scholar
• Gatenby PA, Ramus JR, Caygill CP, Winslet MC, Watson A. Aspirin is not chemoprotective for Barrett's adenocarcinoma of the oesophagus in multicentre cohort. Eur J Cancer Prev 2009;18:381–4.
   PubMedGoogle Scholar
• Das D, Chilton AP, Jankowski JA. Chemoprevention of oesophageal cancer and the AspECT trial. Recent Results Cancer Res 2009;181:161–9.
   PubMedGoogle Scholar
• Konturek PC, Burnat G, Hahn EG. Inhibition of Barret's adenocarcinoma cell growth by simvastatin: involvement of COX-2 and apoptosis-related proteins. J Physiol Pharmacol 2007;58(Suppl 3):141–8.
   PubMed Web of Science ®Google Scholar
• Ogunwobi OO, Beales IL. Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells. Am J Gastroenterol 2008;103:825–37.
   PubMed Web of Science ®Google Scholar